RxDoctor Payments DataLook up a doctor →

Nirav Pavasia, MD

Neurology · Dallas, TXNPI 1740591668

Payments from drug & device makers

$1,957,850in general payments, 2019–2025

Across 2,772 payments — averaging $706.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$349K
  • AbbVie$327K
  • Amneal Pharmaceuticals LLC$300K
  • Neurocrine Biosciences, Inc.$292K
  • Kyowa Kirin, Inc.$156K
  • Eli Lilly$104K
  • plus $429K from 54 others
$7,686in research payments, 2019–2025

Across 15 payments — averaging $512.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K
  • AbbVie$567

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
MDD US Operations, LLC443$349,163
AbbVie(2 entities)321$327,493
Amneal Pharmaceuticals LLC163$299,607
Neurocrine Biosciences, Inc.378$292,394
Kyowa Kirin, Inc.239$156,011
Eli Lilly4$103,817
Acadia Pharmaceuticals Inc300$101,985
Adamas Pharmaceuticals, Inc.117$90,147
UCB SA6$70,883
Teva Pharmaceuticals USA, Inc.90$44,232
Boston Scientific134$36,245
Acorda Therapeutics, Inc53$36,232
Sunovion Pharmaceuticals Inc.68$18,133
Abbott78$16,305
Lundbeck LLC20$4,138
UCB, Inc.52$4,086
Merz Pharmaceuticals, LLC17$565
Ipsen Biopharmaceuticals, Inc16$476
Greenwich Biosciences, Inc.10$473
Pfizer29$458
Novartis20$362
Eisai Inc.15$327
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$237
Lilly USA, LLC13$234
Grifols USA, LLC10$202
Argenx US, Inc.6$200
AstraZeneca9$181
Avion Pharmaceuticals13$180
Akcea Therapeutics, Inc.4$173
Biogen8$169
Genentech USA, Inc.7$164
Octapharma USA, Inc.7$162
SK Life Science, Inc.7$146
Alnylam Pharmaceuticals Inc.6$133
Averitas Pharma Inc.1$122
Avanir Pharmaceuticals, Inc.7$121
Sumitomo Pharma America, Inc.6$119
Medtronic(2 entities)4$118
Biohaven Pharmaceutical Holding Company Ltd.7$114
Merz North America, Inc.4$103
CSL Behring5$99
TG Therapeutics, Inc.4$97
Vertical Pharmaceuticals, LLC6$96
Hospira, Inc.5$84
Biohaven Pharmaceuticals, Inc.4$77
Bristol Myers Squibb4$65
GE HealthCare4$64
Takeda Pharmaceuticals U.S.A., Inc.2$60
Azurity Pharmaceuticals, Inc.3$58
Johnson & Johnson(2 entities)3$51
Arbor Pharmaceuticals, Inc.4$51
Jazz Pharmaceuticals Inc.2$50
Tanabe Pharma America, Inc.3$49
Neurelis, Inc.2$47
Catalyst Pharmaceuticals, Inc.2$47
Supernus Pharmaceuticals, Inc.2$37
Vanda Pharmaceuticals Inc.1$36
Immedica Pharma US, Inc.1$33
Scilex Pharmaceuticals Inc.2$29
Currax Pharmaceuticals LLC2$29

How this compares

$1,957,850 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$645,587
Medicare patients
672
Services billed
28,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →